Sarcoma  >>  itacitinib (INCB039110)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
itacitinib (INCB039110) / Incyte
NCI-2018-00615, NCT03670069: Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Terminated
1
27
US
Itacitinib, 1334298-90-6, 3-Azetidineacetonitrile, INCB039110, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Center, Incyte Corporation
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma
03/23
05/24

Download Options